ERBB2 and breast carcinoma: The treatment strategy of breast cancers has been modified by the identification of different subgroups of this heterogenous disease and emergence of resistance to endocrine therapy till today remains a matter of grave concern in patients with HR+/HER2− advanced/metastatic breast cancer.